- Home
- MIST vs BDTX Comparison
MIST vs BDTX Comparison
Compare MIST & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | BDTX |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.3M | 104.0M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MIST | BDTX |
|---|---|---|
| Price | $0.70 | $1.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | $5.86 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.1M | 610.9K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $147.62 | N/A |
| Revenue Next Year | $476.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $1.60 |
| 52 Week High | $3.06 | $4.94 |
Technical Indicators
Market Signals| Indicator | MIST | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.67 | 47.14 |
| Support Level | N/A | $1.79 |
| Resistance Level | $1.42 | $1.93 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 8.54 | 61.11 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.